Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients

Sponsor
Center Eugene Marquis
Study ID
NCT01836536
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients. Unfortunately some patients fail to respond to this treatment and finding biological factors allowing the discrimination between potential responders and non responders would be very helpful. As the immune system plays a key role in angiogenesis induction and maintenance in cancer, it could serve as a surrogate marker of angiogenesis in cancer patients. The purpose of this study is to determine the influence of bevacizumab treatment on circulating immune cells in high grade glioma patients and to search for a link between the variation of these cells and the response to treatment.

Key Dates

First listed
Apr 22, 2013
Start date
Sep 30, 2012
Status verified
Feb 2017
Primary completion
Mar 31, 2015
Completion
Aug 31, 2015

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Other: BEVACIZUMAB
    BEVACIZUMAB standard of care

Primary Outcome Measure

blood cells populations [ Time Frame: up to 4 months ]

Related Studies